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ABSTRACT Bunyaviruses pose a significant threat to human health, prosperity, and
food security. In response to viral infections, interferons (IFNs) upregulate the ex-
pression of hundreds of interferon-stimulated genes (ISGs), whose cumulative action
can potently inhibit the replication of bunyaviruses. We used a flow cytometry-based
method to screen the ability of 500 unique ISGs from humans and rhesus ma-
caques to inhibit the replication of Bunyamwera orthobunyavirus (BUNV), the proto-
type of both the Peribunyaviridae family and the Bunyavirales order. Candidates pos-
sessing antibunyaviral activity were further examined using a panel of divergent
bunyaviruses. Interestingly, one candidate, ISG20, exhibited potent antibunyaviral ac-
tivity against most viruses examined from the Peribunyaviridae, Hantaviridae, and
Nairoviridae families, whereas phleboviruses (Phenuiviridae) largely escaped inhibi-
tion. Similar to the case against other viruses known to be targeted by ISG20, the
antibunyaviral activity of ISG20 is dependent upon its functional RNase activity.
Through use of an infectious virus-like particle (VLP) assay (based on the BUNV mini-
genome system), we confirmed that gene expression from all 3 viral segments is
strongly inhibited by ISG20. Using in vitro evolution, we generated a substantially
ISG20-resistant BUNV and mapped the determinants of ISG20 sensitivity/resistance.
Taking all the data together, we report that ISG20 is a broad and potent antibunya-
viral factor but that some bunyaviruses are remarkably ISG20 resistant. Thus, ISG20
sensitivity/resistance may influence the pathogenesis of bunyaviruses, many of
which are emerging viruses of clinical or veterinary significance.
IMPORTANCE There are hundreds of bunyaviruses, many of which cause life-
threatening acute diseases in humans and livestock. The interferon (IFN) system is a
key component of innate immunity, and type I IFNs limit bunyaviral propagation
both in vitro and in vivo. Type I IFN signaling results in the upregulation of hundreds
of IFN-stimulated genes (ISGs), whose concerted action generates an “antiviral state.”
Although IFNs are critical in limiting bunyaviral replication and pathogenesis, much
is still unknown about which ISGs inhibit bunyaviruses. Using ISG-expression screen-
ing, we examined the ability of 500 unique ISGs to inhibit Bunyamwera orthobun-
yavirus (BUNV), the prototypical bunyavirus. Using this approach, we identified
ISG20, an interferon-stimulated exonuclease, as a potent inhibitor of BUNV. Interest-
ingly, ISG20 possesses highly selective antibunyaviral activity, with multiple bunyavi-
ruses being potently inhibited while some largely escape inhibition. We speculate
that the ability of some bunyaviruses to escape ISG20 may influence their pathogen-
esis.
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There are over 350 known viruses in the Bunyavirales order (collectively known asbunyaviruses) that were recently reclassified into nine families: Feraviridae, Fimo-
viridae, Hantaviridae, Jonviridae, Nairoviridae, Peribunyaviridae, Phasmaviridae, Phenui-
viridae, and Tospoviridae (1). Most bunyaviruses are carried and transmitted by arthro-
pods, such as mosquitoes, ticks, sand flies, or thrips, except the hantaviruses
(Hantaviridae), which are typically transmitted via infectious aerosols usually originating
from rodent excreta (2). Several bunyaviruses can cause severe human diseases, such as
La Crosse (LACV) and Oropouche (OROV) orthobunyaviruses (Peribunyaviridae family),
Hantaan (HTNV) and Sin Nombre orthohantaviruses (Hantaviridae family), severe fever
with thrombocytopenia syndrome (SFTSV) and Rift Valley fever (RVFV) phleboviruses
(Phenuiviridae family), and Crimean-Congo hemorrhagic fever orthonairovirus (CCHFV)
(Nairoviridae family) (2). Importantly, bunyaviral emergence and reemergence represent
continuous threats to global health and prosperity, and bunyaviruses might have
higher zoonotic potential than that of many other viruses (3). Bunyamwera orthobun-
yavirus (BUNV), the prototype virus of the Peribunyaviridae family and the Bunyavirales
order, remains an important research model for many significant bunyaviral pathogens.
Like most viruses in the Peribunyaviridae family, BUNV possesses a tripartite
negative-sense RNA genome comprised of large (L), medium (M), and small (S) genome
segments. The S segment encodes the nucleocapsid (N) protein and the nonstructural
protein NSs in overlapping reading frames. The M segment encodes a viral glycoprotein
precursor (in the order Gn-NSm-Gc), and the L segment encodes the RNA-dependent
RNA polymerase (2). The glycoprotein precursor is proteolytically cleaved into two
mature viral membrane glycoproteins (Gn and Gc) and a nonstructural protein (NSm)
by the host signal peptidase and signal peptide peptidase (4). Bunyaviruses replicate in
the cytosol and assemble and bud at membranes of the Golgi complex (2). During
genome replication, each genome segment serves as an RNA-dependent RNA poly-
merase template for the generation of positive-sense mRNA and antigenomic RNA
(cRNA). The cRNA subsequently acts as a template for the generation of nascent
genomic RNA (gRNA). Thus, bunyavirus replication involves at least nine distinct RNA
species (2).
Following infection, bunyaviruses are sensed by the host. For example, the RNA
genomes of orthobunyaviruses and phleboviruses carry uncapped 5= triphosphate
(5=-pppRNA) ends and short double-stranded RNA (dsRNA) structures, which can be
sensed by the cytoplasmic RNA helicase, RIG-I (retinoic acid-inducible gene I) (5–7).
Pattern recognition frequently results in the secretion of type I interferons (IFNs), which
modulate multiple immune processes and place cells in an “antiviral state,” impeding
the infection and replication of viruses (8). IFNs are known to inhibit bunyaviruses both
in vitro and in vivo (9–16). Indeed, IFNs likely play a key role in constraining bunyavirus
replication and pathogenesis, as many short-lived asymptomatic infections can become
severely pathogenic when the IFN defenses of the host are compromised (17–22).
Moreover, the importance of host IFN responses in combatting bunyaviral infection is
underscored by the multitude of strategies that bunyaviruses employ to counteract
host IFN responses. The NSs proteins of many bunyaviruses can be major virulence
factors and act as potent IFN antagonists (23–25). These divergent NSs proteins utilize
multiple strategies to inhibit host IFN responses (25, 26), including suppressing host
mRNA transcription (25, 27, 28), blocking pattern recognition (11, 29, 30), or even
disrupting type I IFN signaling by sequestering STAT1 and STAT2 into inclusion bodies
(31).
Although bunyaviruses are potently inhibited by IFNs in vitro and this inhibition
likely helps to define bunyaviral pathogenesis, only a few IFN-stimulated genes (ISGs)
have been ascribed antibunyaviral activity so far (32–36). In this study, using a flow
cytometry-based gain-of-function screening assay, we considered the ability of 488
unique human and macaque ISGs to inhibit the prototypical bunyavirus (BUNV). Here
we show that the antiviral exonuclease ISG20 (37) has broad-spectrum antiviral activity
against multiple bunyaviruses. Similar to that against known targets of ISG20, the
antiviral effect is dependent upon functional exonuclease activity (37–41). Using in vitro
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evolution, we selected an ISG20-resistant BUNV and showed that viral resistance maps
to multiple genome segments. Importantly, even low levels of endogenous ISG20
expression potently inhibited BUNV, whereas some bunyaviruses effectively escaped
inhibition by ISG20. These data suggest that ISG20 may play a key role in the host
response to bunyaviral infection and that sensitivity/resistance to this factor might
therefore influence bunyaviral pathogenesis.
RESULTS
BUNV-EGFP completes a single round of infection in MT4 cells. We previously
reported a “multicycle” screen searching for host factors capable of attenuating BUNV
replication. Under these conditions, IFITM3 and IRF1 were identified as modest inhib-
itors of BUNV replication (42). Because BUNV is highly sensitive to inhibition by type I
IFN in vitro, we hypothesized that additional ISGs with anti-BUNV activity likely exist. We
recently expanded our ISG library to include 350 additional ISGs from rhesus ma-
caques (43), increasing our total library size to 488 unique ISGs (25% more genes).
This encouraged us to search again for interferon-induced effectors that inhibit BUNV.
In order to use arrayed ISG-expression screening (42–45) to identify ISGs with anti-BUNV
activity, we needed to select a cell line that could easily be transduced with ISG-
encoding lentiviral vectors and be susceptible to subsequent infection with BUNV. We
previously used human MT4 T cells for this screening approach (43, 44), so we
examined whether these cells were susceptible to BUNV infection. We utilized recom-
binant BUNV-EGFP, in which enhanced green fluorescent protein (EGFP) is fused with
the N terminus of a truncated Gc glycoprotein (46), as this reporter virus can easily be
used for flow cytometry-based screening assays. Interestingly, although MT4 cells could
readily be infected with BUNV-EGFP (Fig. 1A and B), this virus appeared to be unable to
spread throughout the culture, and the percentage of infected cells decreased over
time (Fig. 1C). The lack of propagation in MT4 cells appeared to be specific to the
recombinant GFP-tagged virus, as wild-type (wt) BUNV replicated efficiently (reaching
titers of over 106 PFU/ml at 48 h postinfection [hpi]), whereas no PFU were produced
FIG 1 BUNV-EGFP completes a single round of infection in MT4 cells. (A) A typical confocal microscopy field of MT4
cells infected with BUNV-EGFP and stained with DAPI (4=,6-diamidino-2-phenylindole). (B) Pseudocolored flow
cytometry dot plots of MT4 cells infected or not infected with BUNV-EGFP. (C) Growth curve for BUNV-EGFP on MT4
cells. MT4 cells were infected with BUNV-GFP at an MOI of 5 (determined using Vero cells). (D) Growth kinetics of
wt BUNV and BUNV-EGFP in MT4 cells. MT4 cells were infected with wt BUNV or BUNV-EGFP, using the same MOI.
At different time points, the supernatant was harvested and the infectious titer determined using Vero cells. (E)
Plaques of wt BUNV and BUNV-EGFP (on Vero cells) produced by MT4 cells.
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with BUNV-EGFP at an equivalent multiplicity of infection (MOI) (Fig. 1D and E). The
exact mechanism that prevented BUNV-EGFP propagation in MT4 cells is unknown, but
the formation of abundant virus-like GFP puncta (Fig. 1A) suggested that BUNV-EGFP
may efficiently express multiple viral genes and complete much of the viral life cycle in
these cells. Construction of BUNV-EGFP required deleting 350 residues from the N
terminus of Gc to accommodate the GFP moiety. It is therefore possible that the N
terminus of Gc is essential for the efficient generation of infectious BUNV progeny in
MT4 cells but is dispensable in other contexts (46, 47).
ISG-expression screening reveals candidate genes with anti-BUNV activity. The
unanticipated single round of infection of BUNV-EGFP in MT4 cells enabled us to
conduct a screen searching for ISGs that inhibit the early stages of the BUNV life cycle
(after viral gene expression but before the genesis of infectious progeny). Arrayed
ISG-expression screening involves exogenously expressing ISGs within target cells that
are susceptible to infection by the virus of interest (43–45). Under screening conditions,
not all the cells in a well will express the ISG. Viruses can therefore replicate efficiently
in the ISG-negative cells, and abundant progeny virus can overwhelm a protective ISG
in adjacent cells. Thus, “multicycle” ISG-expression screens can potentially underesti-
mate the protective effect of some ISGs, and limiting the virus to a single round of
infection may improve the identification of candidate antiviral factors. Thus, we took
advantage of the late defect in BUNV-EGFP replication in MT4 cells to examine the
ability of 488 different ISGs to inhibit a single round of BUNV infection (Fig. 2A to D).
We considered ISGs from Homo sapiens and Macaca mulatta (43), as both primate
species likely support BUNV infection (48, 49). The protective effect of each ISG was
quantified using two-color flow cytometry (Fig. 2C), and the level of infection in the
presence of each ISG was plotted as a percentage of the screen average (Fig. 2D).
Multiple ISGs conferred considerable protection from BUNV infection in the initial
screen (Fig. 2D). Many of the candidate anti-BUNV ISGs were known restriction factors
(such as ISG20, IFITM3, and Mx1). In addition, multiple ISGs (such as IRF1 and IRF7) likely
conferred protection by engendering a polygenic antiviral state by stimulating IFN
expression or interferon-stimulated response element (ISRE)-driven transcription (43).
To validate the screening results, independent lentiviral vector preparations were
used to consider the ability of the 20 most protective human and macaque candidate
antiviral ISGs to protect MT4 cells from titrated BUNV-EGFP challenge (Fig. 2E). This
confirmed the ability of the exogenously expressed ISGs to confer protection from
BUNV infection. Nine human ISGs and 5 macaque ISGs which conferred 5-fold
protection were selected for further investigation (Fig. 2E; Tables 1 and 2).
ISG20 has specific antibunyaviral activity. Many divergent viruses are classed as
bunyaviruses (1, 2). To further investigate the antiviral spectra of the selected ISGs
against bunyaviruses, we screened the ability of each ISG which conferred 5-fold
protection from BUNV to inhibit a panel of 15 divergent bunyaviruses (including
members of four distinct families). Our panel included viruses that can cause serious
clinical infections, such as heartland phlebovirus (HRTV) and SFTSV, as well as agricul-
tural pathogens, such as Schmallenberg orthobunyavirus (SBV). To compare these
divergent viruses, we used Vero cells, which support the efficient propagation of many
divergent viruses due in part to their defective IFNB1 gene (50). To ensure stable
phenotypes, we established Vero cell clones that were transduced with vectors encod-
ing human EHD4, HK2, IFITM3, IRF1, ISG20, NOS2A, or SCO2 in addition to clones
modified to express macaque ISG20, LGALS9, or RHOB. Single-cell clones were selected
that had BUNV-inhibitory profiles similar to those of the parental “bulk” population
from which they were derived. We were unable to establish stable cell lines expressing
IDO1, BCL3, or PFKFB3. The broad-spectrum antiviral activity of IDO1, through trypto-
phan depletion, is well documented (43), and persistent tryptophan depletion likely
inhibited the generation of single-cell clones. We reasoned that the ability of BCL3 and
PFKFB3 to perturb normal Vero cell physiology (preventing the generation of stable cell
lines) made it less likely that these ISGs possessed direct anti-BUNV activity and more
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likely that the global cellular effect of overexpressing these genes reduced BUNV
infectivity. Thus, we did not consider IDO1, BCL3, or PFKFB3 further. We confirmed the
expression of eight ISGs by Western blotting (Fig. 3A). However, we were unable to
establish Western blotting conditions that detected NOS2A or RHOB. We also assessed
the transduction and clonality of each cell line by monitoring red fluorescent protein
(RFP) expression from the lentiviral vector (Fig. 3B). We then conducted a miniscreen of
the 10 remaining ISGs (7 human and 3 macaque ISGs) and assessed the virus yields for
our panel of bunyaviruses in the presence of each ISG (Fig. 3C). Because one clone of
each ISG was investigated, we used this miniscreen approach to select candidates for
subsequent examination, and the miniscreen does not constitute a precise survey of
ISGs that inhibit representative bunyaviruses. Moreover, NOS2A caused little inhibition
of any of our panel of viruses. Without further investigation, it is impossible to discern
whether NOS2A was poorly expressed or has limited antibunyaviral activity. Nonethe-
less, some patterns emerged, and the inhibitory effects of each ISG on our panel of
bunyaviruses are summarized in the heat map in Fig. 3D.
As observed in previous studies, exogenous IRF1 expression initiated a gene ex-
pression program (43) that led to the inhibition of most bunyaviruses. IFITM3, a
FIG 2 ISG-expression screening reveals novel candidate genes with anti-BUNV activity. (A) Schematic representation of H. sapiens and M.
mulatta ISG libraries. The libraries are in a 96-well plate format with one ISG per well. (B) Simplified schematic of the pSCRPSY-DEST
lentiviral vector (the dotted line indicates mRNA splicing). (C) Schematic representation of the ISG screen. MT4 cells were transduced with
the ISG libraries. After 48 h, cells were challenged with BUNV-EGFP, and the infectivity of BUNV-EGFP in ISG-expressing MT4 cells was
quantified by flow cytometry at 48 hpi. (D) Results of the screen. Each dot represents one ISG. Infectivity measured for each ISG-expressing
well was normalized to the average for the screen, which is indicated as 100%. (E) Confirmatory assays for the selected top 20 H. sapiens
and M. mulatta candidate inhibitory ISGs. New lentiviral stocks independent of the primary screen were made and used to transduce MT4
cells. BUNV-EGFP infection was performed as in the primary screen. Titers are presented as numbers of GFP infectious units (IU) per
milliliter and were calculated for triplicate wells.
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well-characterized restriction factor that inhibits the fusion of cellular and viral mem-
branes (51), appeared to have broad-spectrum antibunyaviral activity. IFITM3 reduced
the infectious yield and/or plaque area for most of the members of our panel of
bunyaviruses. The magnitude of protection was variable, as IFITM3 potently inhibited
several viruses (such as Kairi orthobunyavirus [KRIV], SBV, Dugbe orthonairovirus
[DUGV], and HRTV), whereas other viruses were only weakly inhibited or not inhibited
at all (such as OROV and Puumala orthohantavirus [PUUV]). IFITM3 has previously been
described to inhibit multiple bunyaviruses (36, 52). Exogenous EHD4 also potently
inhibited multiple bunyaviruses (including SBV, Batama orthobunyavirus [BMAV], and
PUUV), while some viruses were unaffected. Whether this inhibition is physiologically
relevant is questionable, as EHD4 is usually expressed at low levels and is only weakly
stimulated by IFNs (53, 54). Exogenous HK2 and RHOB caused substantial inhibition in
some settings and potently inhibited BUNV and SBV, respectively. However, HK2 and
RHOB typically caused only modest inhibition of our panel of viruses.
TABLE 1 Results of confirmatory assays for H. sapiens ISGs
Rank Gene symbol Product name
Fold inhibition
(ISGs/empty SCRPSY)
1 IRF1 Interferon regulatory factor 1 13.94188652
2 IFITM3 Interferon-induced transmembrane protein 3 10.81898208
3 ISG20 Interferon-stimulated exonuclease gene, 20 kDa 10.51226219
4 EHD4 EH domain-containing protein 4 8.337769295
5 NOS2A Nitric oxide synthase 2a 8.142114105
6 INDO/IDO Indoleamine-pyrrole 2,3-dioxygenase 7.431693179
7 SCO2 SCO cytochrome oxidase-deficient homolog 2 6.682186081
8 HK2 Hexokinase 2 6.600853655
9 BCL3 B-cell CLL/lymphoma 3 5.560601225
10 IRF7 Interferon regulatory factor 7 4.996490044
11 C5ORF39 Annexin A2 receptor 4.532151199
12 NUP50 Nucleoporin, 50 kDa 4.502720506
13 OAS2 2=,5=-Oligoadenylate synthetase 2 3.857183543
14 TLK2 Tousled-like kinase 2 3.560273013
15 PXK PX domain-containing serine/threonine kinase-like protein 3.333094361
16 MX1 Myxovirus (influenza virus) resistance 1 3.019964468
17 IFIT5 Interferon-induced protein with tetratricopeptide repeats 5 2.697749553
18 LGALS9 Galectin 9, beta-galactoside-binding protein 2.222739332
19 CCNA1 Cyclin A1 2.017553608
20 TNFRSF10A Tumor necrosis factor receptor superfamily, member 10a 1.181220011
TABLE 2 Results of confirmatory assays for M. mulatta ISGs
Rank Gene symbol Product name
Fold inhibition
(ISGs/empty SCRPSY)
1 IFN1 Beta interferon 1 25.68764253
2 ISG20 Interferon-stimulated exonuclease gene, 20 kDa 16.51376275
3 INDO/IDO Indoleamine-pyrrole 2,3-dioxygenase 11.89015349
4 LGALS9 Galectin 9, beta-galactoside-binding protein 6.99430233
5 PFKFB3 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 5.758834317
6 RHOB Ras homolog family member B 5.195047578
7 BCL3 B-cell CLL/lymphoma 3 4.754072894
8 TLK2 Tousled-like kinase 2 4.709891813
9 ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3, isotype 4.611043388
10 IRF7 Interferon regulatory factor 7 4.174521863
11 CCNA1 Cyclin A1 3.389544757
12 IFITM3 Interferon-induced transmembrane protein 3 3.301078884
13 HK2 Hexokinase 2 3.060345699
14 PXK PX domain-containing serine/threonine kinase-like protein 2.855499432
15 IRF1iso3 Interferon regulatory factor 1, isotype 2.770775682
16 IFITM3 Interferon-induced transmembrane protein 3 2.64956607
17 IFITM2 Interferon-induced transmembrane protein 2 2.495300874
18 IFIT5 Interferon-induced protein with tetratricopeptide repeats 5 1.868064022
19 ZNF385B Zinc finger protein 385B 1.802174105
20 TNFRSF10A Tumor necrosis factor receptor superfamily, member 10a 1.363085906
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FIG 3 Antibunyaviral activities of candidate ISGs against a panel of divergent bunyaviruses. (A) ISG expression in 10 Vero-ISG-expressing cell lines
in addition to “empty vector” and naive Vero cell controls was assessed using Western blotting (assays were not established for NOS2A and RHOB).
(Continued on next page)
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In contrast to the other ISGs, human and macaque ISG20 potently inhibited the
majority of our panel of bunyaviruses (Fig. 3E), in some cases reducing the virus yield
1,000-fold (PUUV and KRIV). Intriguingly, while most bunyaviruses were susceptible to
ISG20, Anopheles A orthobunyavirus (ANAV), Capim orthobunyavirus (CAPV), and the
three tested phleboviruses (Phenuiviridae family) were largely resistant. ISG20 is an
important antiviral exonuclease (37) that has maintained robust interferon stimulation
for hundreds of millions of years (54) and has possibly played a key antiviral role
throughout this time, with antiviral activity against multiple viruses being documented
(37–41). Hitherto, ISG20 has not been ascribed antibunyaviral activity, and the obser-
vation that the potent antiviral activity is evaded by multiple viruses suggests that
ISG20 directly inhibits specific bunyaviruses (as opposed to inducing global cellular
effects). We therefore focused our attention on this ISG.
Exonuclease activity underpins ISG20-mediated antibunyaviral activity. Multi-
ple viruses have previously been shown to be sensitive to ISG20, with the majority of
inhibition being dependent on ISG20’s 3=-to-5= exonuclease activity (37–41). A single
substitution (D94G), part of the DEDDh motif in ISG20’s active site (55), can abrogate
exonuclease activity and ablate the inhibition of a number of viruses (37–41, 56). To
investigate whether exonuclease activity is essential for anti-BUNV activity, we gener-
ated cell lines that expressed catalytically inactive forms of human and macaque ISG20
(D94G mutants). While the expression of human and macaque orthologs both reduced
the infectious yield of BUNV (by100-fold and10-fold, respectively) and substantially
reduced the area of individual BUNV plaques, the catalytically defective mutants had no
detectable antiviral activity even though they were expressed at similar levels (Fig. 4B
to E).
Our screen of a panel of bunyaviruses indicated that human ISG20 might generally
possess more potent antibunyaviral activity than that of the macaque ortholog (Fig. 3
and 4A to E), even though the sequences are 98% identical (at the amino acid level),
differing at just 4 amino acid positions (Fig. 4A). Intriguingly, macaque ISG20 also
appeared to be more active against CAPV (Fig. 3C), suggesting that ISG20 orthologs
might possess divergent antibunyaviral specificities. As Western blot analysis revealed
greater expression levels of ISG20 in our human clone (Fig. 3A and 4E), we examined
“bulk populations” of Vero cells transduced in parallel with human and macaque ISG20
and found that these bulk populations appeared to express equivalent levels of the
ISG20 proteins (Fig. 4F). Importantly, in this context, human and macaque ISG20
inhibited BUNV to similar degrees (Fig. 4G). Crucially, the highly specific antibunyaviral
activity of ISG20 was also evident in these bulk populations, as parallel infections with
single-cycle RVFV (strain 35/74) (57) were completely unaffected by ISG20 (Fig. 4G). We
therefore speculate that any observed species-specific variation in ISG20 activity (Fig.
3C) is perhaps due to different ISG20 expression levels and clonal variation. However,
we cannot exclude the possibility that primate ISG20 orthologs may possess divergent
antibunyaviral specificities.
Gene expression from all BUNV genome segments is inhibited by ISG20. BUNV
possesses a tripartite (L, M, and S segments), single-stranded, negative-sense RNA
genome. To investigate whether ISG20 targets a specific genome segment or all three
segments, we assessed the inhibitory effect of ISG20 on virus-like particle (VLP)-based
reporter gene expression. In this assay, infectious VLPs (iVLPs) were utilized that
contained a single BUNV minigenome derived from just one of the three segments. The
iVLPs were assembled in BSRT7/5 cells by supplying all the essential viral proteins (L
FIG 3 Legend (Continued)
(B) For the ISGs in panel A, lentiviral vector-encoded TagRFP expression was monitored by flow cytometry. (C) Infectious virus yields from 10
Vero-ISG-expressing cell lines. Cells were infected with 15 wild-type bunyaviruses representing four families. Supernatants were collected, and virus
yields were determined on Vero or BHK-21 cells. The MOIs and time points of supernatant harvest were as follows: for BUNV, CVV, KRIV, SBV, DUGV,
RVFV, and SFTSV, MOI of 0.001 and 72 hpi; for OROV, MOI of 0.001 and 48 hpi; for ANAV, BMAV, BORV, CAPV, and TCMV, MOI of 0.01 and 48 hpi;
for PUUV, MOI of 0.1 and 48 hpi; and for HRTV, MOI of 0.01 and 72 hpi. EMPTY, Vero cells transduced with empty SCRPSY lentiviral stocks. (D) Heat
map analysis (generated by GraphPad Prism 7) of the effects of 10 ISGs on the yields of 15 bunyaviruses. (E) Summary of human ISG20’s antiviral
effects on 15 bunyaviruses.
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protein, Gn and Gc viral glycoproteins, and N protein) in trans together with a single
minigenome transcription vector [either pT7riboBUNLRen(), pT7riboBUNMRen(),
or pT7riboBUNSRen()] representing each genome segment. The minigenomes con-
tained the full-length 5= and 3= untranslated regions (UTRs) of BUNV, with the Renilla
luciferase gene inserted in place of the viral open reading frame (ORF) in each segment.
The iVLPs were used to infect Vero cells expressing either wt ISG20 or ISG20D94G.
Interestingly, all three minigenome segments were targeted, and luciferase expression
from the L, M, and S segments was substantially reduced by ISG20 (Fig. 5A). This 5-
to 10-fold reduction was entirely dependent on functional exonuclease activity, as the
D94G catalytic mutant caused no inhibition of reporter gene expression (Fig. 5A).
We next considered which RNA species might be targeted by ISG20, as multiple RNA
forms derived from each genome segment are required for the bunyaviral life cycle.
Thus, viral genomic RNA (gRNA), antigenomic RNA (cRNA), and mRNA species could all
FIG 4 A single point mutation in the active site (ISG20D94G) abolishes the antibunyaviral activity of ISG20. (A) Schematic representation of the three exonuclease
active motifs (Exo I, II, and III) of ISG20 (shown in gray boxes). The conserved amino acid residues (from the DEDDh family) are highlighted in green. The Asp94
residue (shown in green) of wild-type ISG20 was replaced with Gly to generate the catalytically inactive mutant ISG20D94G. The four amino acid differences
between the human (H.s) and macaque (M.m) ISG20 proteins are highlighted with yellow boxes and red letters. (B) Plaque phenotypes of wt BUNV on
Vero-EMPTY and Vero-ISG20/ISG20D94G cells. (C and D) Quantification of plaque areas (C) and virus titers (D) of BUNV on Vero-EMPTY and Vero-ISG20/ISG20D94G
cells. (E) Western blot showing ISG20/ISG20D94G protein expression. Cell lysates were probed with an anti-ISG20 polyclonal antibody. Tubulin served as a sample
loading control. (F) Same as panel E, but using bulk populations of Vero cells expressing human and macaque ISG20. (G) Titration curves for the bulk populations
from panel F infected with BUNV-EGFP (46) or single-cycle RVFV (57). Means and standard deviations (SD) for triplicate titrations are shown.
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FIG 5 Gene expression from all BUNV genome segments is inhibited by ISG20. (A) Serially diluted single-segment VLPs were used to
infect Vero-EMPTY, Vero-ISG20, and Vero-ISG20D94G cells. At 24 hpi, cells were lysed for testing of Renilla luciferase activity (mean 
SD; n  3), and luciferase activity at the indicated VLP inoculum (in microliters) is shown. (B) Antiviral effects of interferon on
single-segment VLPs. Unmodified naive Vero cells were treated or mock treated with 1,000 U/ml universal interferon for 24 h. The cells
were subsequently infected with 200 l of serially diluted VLPs. After 24 h, cells were lysed for testing of Renilla luciferase activity
(mean  SD; n  3). (C) RT-qPCR strategies for detection of BUNV S-segment RNAs. Strand-specific tagged reverse transcription
primers were used to generate cDNAs for S-segment genomic RNA (gRNA), antigenomic RNA (cRNA), and mRNA, which were
subsequently analyzed by qPCR. The mRNA qPCR primers amplify all positive-sense viral RNAs. Using cRNA-specific qPCR primers,
mRNA was quantified by subtracting the cRNA abundance from the abundance of all positive-sense viral RNAs. Arrows show qPCR
primers, red bars show the TaqMan probe sequence, yellow balls show the 6-carboxyfluorescein (FAM) fluorescent dye, and black balls
show Black Hole Quencher 1. (D) Validation of primer specificity. gRNA, cRNA, and mRNA (in vitro-transcribed standards) (5  106
(Continued on next page)
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conceivably be targets of ISG20. We were not aware of existing bunyaviral strand-
specific quantitative PCR (qPCR) assays, so based on published norovirus and influenza
A virus strategies (58, 59), we developed a tagged TaqMan quantitative reverse
transcription-PCR (qRT-PCR) assay that efficiently detects the desired S-segment RNA
species but poorly amplifies undesired/nonspecific targets. The exception was mRNA,
whose entire sequence is also present in the cRNA species, except for the “cap-
snatched,” host cell-derived 5= end (Fig. 5C). In this instance, we estimated the mRNA
copy number by subtracting the cRNA copy number from the value obtained from the
mRNA assay (which detects all positive-sense viral RNAs). Validation of the assay
specificity is shown in Fig. 5D. Since a single cycle of BUNV infection in Vero cells is
approximately 6 h (46), we examined the S segment at 0, 2, 4, and 6 h postinfection.
Using this approach, all three S-segment RNAs appeared to be diminished substantially
(10-fold) by ISG20 following infection of Vero cells (Fig. 5E). However, we were unable
to discern whether this reduction was due to the S-segment RNAs being degraded by
ISG20 or was an indirect consequence of ISG20 inhibiting some other facet(s) of the
BUNV life cycle.
Mapping the viral determinants of ISG20 antiviral activity. In vitro evolution/
serial passaging has often been employed to study the antiviral mechanisms of many
antiviral factors and frequently reveals the sensitivity determinants that represent a
molecular interface between host and pathogen (60–64). To investigate whether BUNV
can access sequence space that confers resistance to ISG20, we passaged BUNV in Vero
cells expressing human ISG20 (or modified using empty vector). We periodically
monitored the ability of the passaged swarm to plaque/replicate in the presence of
ISG20. Following 20 passages, partial ISG20 resistance was observed, and after 40
passages in the presence of ISG20, we were able to isolate a viral swarm that replicated
far more efficiently in the presence of ISG20, forming larger plaques and yielding more
infectious particles (Fig. 6A to C). This P40 virus replicated substantially faster than the
parental virus in the presence of ISG20, yielding 100-fold more virus at 48 hpi (Fig.
6C). Crucially, the P40 virus was weakly attenuated on naive Vero cells, suggesting that
the ISG20 resistance was not merely due to adaptation to Vero cells during the passage
series (Fig. 6C).
To investigate the viral determinants that rendered BUNV resistant to ISG20, we
sequenced the L, M, and S segments of the P20 and P40 swarms by using direct
sequencing of RT-PCR products. The sequences of the termini were also simultaneously
determined using 3= rapid amplification of cDNA ends (RACE). Sequence analysis
revealed mutations in all three segments at P20 and P40, some of which were transient
polymorphisms. By P20, apart from a reversion to the GenBank sequence (A3568G; M
segment), only a single mutation was selected to near uniformity in the presence of
ISG20 (Table 3). This S-segment mutation (A330C) encodes changes in the N (N82T) and
NSs proteins (T76P) and is possibly the major determinant of the ISG20 resistance
observed at P20. Sequencing of the P40 swarm revealed multiple mutations in all
genome segments that had been selected to near uniformity (Table 3). Importantly,
none of these mutations were found in the P40 virus passaged on Vero-EMPTY cells
(Table 4).
To assess the significance of these mutations, we generated reassortant viruses that
contained parental and P40 mutant genome segments [the “=” symbol denotes the
mutant segment(s) used] by using reverse genetics. Importantly, a virus rescued with all
three P40 genome segments (designated rBUN-L=M=S=) recapitulated the phenotype of
the P40 swarm and replicated more efficiently than the wt virus in the presence of
ISG20 (Fig. 6D). In accordance with the observation that ISG20 inhibits gene expression
FIG 5 Legend (Continued)
copies) were reverse transcribed using gRNA, cRNA, and mRNA RT primers, respectively. cDNA was then quantified using strand-
specific qPCR primers. (E) Vero-EMPTY or Vero-ISG20/ISG20D94G cells were infected with wt BUNV at an MOI of 10. At 0, 2, 4, and
6 hpi, cells were lysed with TRIzol and total cellular RNA was extracted for RT-qPCR analysis of S-segment RNAs (data are
means  SD; n  3).
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FIG 6 Generation of ISG20-resistant BUNV and demonstration that endogenous ISG20 possesses antibunyaviral activity. (A and B) Plaque phenotypes (on Vero
and Vero-ISG20 cells) (A) and fold inhibition (B) of the parental virus and the P20 and P40 ISG20-resistant viruses by ISG20 (fold reductions in PFU per milliliter
for comparisons of naive and Vero-ISG20 cells). (C) Comparison of growth curves for the parental virus and the P40 virus on Vero-ISG20 and naive Vero cells.
Cells were infected at an MOI of 0.01 (data are means  SD; n  3). (D) Infectious yields (36 h after infection at an MOI of 0.01) of wild-type (wt) BUNV and
reassortant mutants (mutant segments are denoted by “=”) from Vero-ISG20 or Vero-D94G cells (data are means and ranges; n  2). (E) Biological IFN assays
to assess the ability of supernatants from HeLa cells infected with the indicated viruses to inhibit the replication of EMCV in A549-Npro cells. (F) Western blot
analysis of basal and inducible expression in naive HeLa cells, HeLa-shGFP cells, and HeLa-shISG20 cells. Basal expression or universal interferon (500
U/ml)-induced ISG20 expression was stably detected in naive HeLa cells and HeLa-shGFP cells, whereas both basal and inducible ISG20 expression was
undetectable in HeLa-shISG20 cells. (G) Growth curves for parental BUNV, P40 Vero-EMPTY-passaged BUNV, and P40 ISG20-resistant BUNV on HeLa cells (MOI
0.01) (data are means  SD; n  3). (H) Growth curves for parental BUNV and P40 ISG20-resistant BUNV on HeLa-shGFP (control) and HeLa-shISG20 cells.
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from all three genome segments (Fig. 5A), the addition of a single P40 genome
segment was not sufficient to confer equivalent ISG20 resistance to the L=M=S= virus
(Fig. 6D). Moreover, the contribution of each individual mutant segment to ISG20
resistance appeared to be unequal, with S= and M= conferring more substantial resis-
tance than that seen with L=. Thus, ISG20 resistance appears to be multipartite, and
mutations are required on more than one genome segment for the P40 virus to resist
ISG20. Because the mutant S= segment encoded two substitutions in NSs (S3L and
T76P), we wondered whether the mutant NSs protein still functioned as an interferon
antagonist. Interestingly, the mutant NSs protein appeared to have reduced activity as
an IFN antagonist in an encephalomyocarditis virus (EMCV) inhibition assay (Fig. 6E).
Endogenous ISG20 has anti-BUNV activity. A recurrent obstacle in understanding
how the IFN-induced “antiviral state” inhibits a virus is that viruses are often simulta-
neously inhibited by multiple IFN-induced defenses. In this scenario, loss-of-function
experiments can be challenging, as viral replication might not be rescued substantially
TABLE 3 Nucleotide and amino acid changes of BUNV passaged on Vero-ISG20 cellsa
Segment Position (nt)
Nucleotide
mutation
Amino acid mutation NoteP0 P20 P40
L 3,257 G G A Synonymous
5,267 A A G I1740M L protein
6,538 A A/Gb G E2163A L protein
M 518 T T/Ab T Synonymous
1,371 G G/Ab G V439I NSm
3,568 A Gc Gc N1171S Gc protein
4,388 A A/Gb G None cRNA 3= UTR
S 112 C C/Tb T Synonymous N protein
S3L NSs protein
330 A C C N82T N protein
T76P NSs protein
aThe following differences were observed in the P0 virus relative to the sequence in GenBank: for the L
segment (accession number NC_001925.1), T5501C (silent) mutation and 6,809-nucleotide C insertion in the
5= UTR; for the M segment (accession number NC_001926.1), G415A (R120K), A417G (K121E), G1423A
(R456K), A1941G (S629G), C2638T (P861L), G2829A (E925K), T3359C (silent), G3568A (S1171N), A4008G
(R1381G), and G4317A (A1421T); and for the S segment (accession number NC_001927.1), not available.
bPolymorphism.
cReversion to the GenBank sequence.
TABLE 4 Nucleotide and amino acid changes of BUNV passaged on Vero-EMPTY cellsa
Segment Position (nt)
Nucleotide mutation
Amino acid mutation NoteP0 P20 P40
L 3,299 A A T Synonymous
3,622 A A A/Gb E1191G L protein
M 518 T T/Ab T Synonymous
1,371 G G/Ab G V439I NSm
2,500 C T T P815L Gc protein
4,240 T T/Ab A I1395N Gc protein
S 84 T T C None 3= UTR
118 T T C Synonymous N protein
L5P NSs protein
165 A G G K27R N protein
S21G NSs protein
aThe following differences were observed in the P0 virus relative to the sequence in GenBank: for the L
segment (accession number NC_001925.1), T5501C (silent) mutation and 6,809-nucleotide C insertion in the
5= UTR; for the M segment (accession number NC_001926.1), G415A (R120K), A417G (K121E), G1423A
(R456K), A1941G (S629G), C2638T (P861L), G2829A (E925K), T3359C (silent), G3568A (S1171N), A4008G
(R1381G), and G4317A (A1421T); and for the S segment (accession number NC_001927.1), not available.
bPolymorphism.
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by removing a single ISG (because multiple inhibitory effectors might still be fully
active). Thus, we searched for cell lines that expressed readily detectable ISG20 without
the need for prior stimulation. HeLa cells are known to express ISG20 in the absence of
IFN treatment (37, 38) (Fig. 6F). Accordingly, the ISG20-resistant swarm grew far more
efficiently than the parental virus in unmodified HeLa cells, with the P40 virus yielding
100-fold more virus at 24 h postinfection (Fig. 6G). However, the control P40 virus
(Vero-EMPTY) did not exhibit any growth advantage on unmodified HeLa cells (Fig. 6G,
green line). Crucially, this difference between the P40 ISG20-resistant virus and the
parental virus was largely due to endogenous ISG20, as short hairpin RNA (shRNA)-
mediated knockdown of ISG20 increased the replication of the parental virus so that it
replicated with kinetics similar to those of the P40 virus (Fig. 6H). Thus, even low levels
of endogenous ISG20 can cause substantial inhibition of BUNV, suggesting that IFN-
induced upregulation of ISG20 (Fig. 6F) likely represents a formidable block to the
replication of BUNV and other sensitive bunyaviruses.
DISCUSSION
Interferons rapidly engender an “antiviral state” in host cells through the induction
and expression of hundreds of ISGs, many of which have antiviral functions. It is well
documented that interferons can suppress the replication of divergent bunyaviruses
both in vitro and in vivo (9–15). In this study, we screened 488 ISGs and identified
multiple ISGs that inhibited the prototypical bunyavirus (BUNV). We revealed that ISG20
exhibits potent and highly specific antibunyaviral activity. ISG20 is robustly upregulated
in response to interferons, and the ISG20 promoter contains ISRE and GAS elements
that respond to type I, type II, and type III interferons (38, 65). Multiple studies have
highlighted the importance of ISG20 as an antiviral effector that targets multiple viruses
(37–41), and several bunyaviruses can be added to the growing list of ISG20 targets.
Thus, ISG20-mediated inhibition may constrain bunyaviral replication as part of an
interferon response, and this targeted activity of ISG20 may limit the pathogenesis of
specific bunyaviruses.
We previously screened the ability of over 350 human ISGs to inhibit BUNV in Huh7
cells and did not identify any candidates that inhibited BUNV2-fold (42). Nonetheless,
the most inhibitory ISGs (IFITM3 and IRF1) were reidentified in this study. Crucially,
ISG20 has been reported to lack specific antiviral activity in Huh7 cells (41), potentially
explaining why ISG20 was not ascribed antibunyaviral activity in previous screens.
Moreover, the unanticipated single round of BUNV-EGFP infection in MT4 cells likely
increased the fidelity of the primary screen, facilitating the identification of multiple
candidate effectors in this study.
A few ISGs previously reported to inhibit BUNV (PKR, IFI44, and Viperin) (32) were not
reidentified in our primary screen. Notably, we were unable to achieve efficient
transduction with PKR-encoding SCRPSY vectors (43), possibly explaining the lack of
antiviral activity in this primary screen. Akin to ISG20 in Huh7 cells, multiple ISGs
possess cell-type-dependent activity. Accordingly, parallel screens with different cell
lines can identify different antiviral candidates (43). Thus, the anti-BUNV activity of IFI44
and Viperin may be context dependent or might simply block the virus life cycle after
efficient GFP expression is achieved (further work would be necessary to explore either
possibility).
The antiviral activity of ISG20 appeared to rely on its 3=-to-5= exoribonuclease
function, as a single amino acid substitution within the active site (D94G) abrogated
antiviral activity. However, it is possible that disrupting this coordinating residue grossly
alters the structure of ISG20, placing a slight caveat on this interpretation. In contrast
to RNase L, an interferon-stimulated RNase that indiscriminately cleaves single-stranded
RNA following UU and UA motifs, ISG20 is able to discriminate between self RNAs
(rRNAs [38, 39] and -actin mRNA [40]) and nonself (viral) RNAs. Similarly, we observed
that Vero cells expressing exogenous ISG20 appeared to be healthy (38) and that
plasmid-based expression was equally efficient in Vero-ISG20 and control cell lines (our
unpublished observations). Nonetheless, it seems likely that host RNAs do not com-
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pletely escape ISG20 because, in accordance with previous observations (56), Vero cells
modified to express ISG20 proliferated more slowly than unmodified cells (unpublished
observations). Importantly, the fact that all the phleboviruses we tested (RVFV strains
MP12 and 35/74, SFTSV, and, to a lesser extent, HRTV) and two orthobunyaviruses
(CAPV and, to a lesser extent, ANAV) largely escaped ISG20-mediated inhibition under-
scores the high level of target specificity exhibited by ISG20. Whether these resistant
viruses actively antagonize ISG20 function (by deploying viral countermeasures) or
evade inhibition through minimizing sequence/structural motifs targeted by ISG20 is
worthy of future investigation. We currently have no information on whether bunya-
viral protein or RNA is predominantly involved, and the precise viral sensitivity/
resistance determinants that underlie ISG20’s selective antibunyaviral activity are com-
pletely unknown (and may influence the pathogenicity of bunyaviruses).
Interestingly, although ISG20 is highly specific, all three luciferase-encoding minig-
enomes (reminiscent of each BUNV genome segment) were targeted by ISG20. The VLP
system we used can complete only a single round of infection yet was potently
inhibited by ISG20. Thus, ISG20 may represent a rapid and effective block to the
bunyavirus life cycle. Crucially, viral replication and transcription in the VLP-infected
cells were carried out by ribonucleoproteins (RNPs) packaged into the VLPs, in which
only one minigenome species (representing a specific genome segment) was present.
Therefore, efficient reporter gene expression was not dependent upon gene expression
from other genome segments, and under these conditions, ISG20 could not mediate
indirect inhibition by targeting another genome segment. Thus, it is likely that follow-
ing VLP infection, ISG20 directly targeted the L, M, and S minigenome segments. One
possible caveat is that the minigenome segments are considerably shorter than the wt
segments and therefore might not fully recapitulate the ISG20 sensitivity/resistance of
the complete segments. Moreover, internal RNA structures can govern sensitivity/
resistance to ISG20 inhibition (38), and we cannot rule out the possibility that the
luciferase ORF constitutes a particularly attractive target for ISG20.
Because BUNV genome replication and gene expression are tightly coupled, it is
unclear whether minigenome gRNA, cRNA, mRNA, or a combination of these species is
targeted by ISG20. Using qRT-PCR, we further examined the S-segment RNA in the
context of replication-competent unmodified BUNV. The quantification of three
S-segment RNAs (gRNA, cRNA, and mRNA) indicated that the abundances of all three
were decreased by ISG20. Considering the VLP data and these qPCR data together, it
seems likely that S-segment RNAs are directly targeted by ISG20. However, we cannot
exclude the possibility that the observed reduction in S-segment RNAs was an indirect
consequence of reduced viral polymerase activity caused by ISG20 inhibiting another
aspect of the BUNV life cycle.
Development of an ISG20-resistant BUNV through in vitro evolution revealed mul-
tiple viral determinants of ISG20 antiviral sensitivity/resistance. The mutations required
for ISG20 resistance did not map to a single genome segment, and instead, changes
were observed in all three segments. Although individual mutant segments could
increase virus growth in the face of ISG20, no single mutant segment could recapitulate
the considerable resistance observed using all three mutant segments. This polygenic
resistance profile considered with the sensitivity of all three minigenomes to ISG20-
mediated inhibition suggests that multiple BUNV RNA segments are likely targets of
ISG20. We speculate that if all genome segments are targeted by ISG20, then mutations
of each segment may plausibly make these viral RNAs less attractive substrates for
ISG20. Notably, the only M-segment mutation selected in the presence of ISG20 was in
a noncoding region (A4388G), excluding reversion to the GenBank sequence. This
observation suggests that BUNV RNA sequence or structural elements might define
sensitivity/resistance to ISG20. However, we cannot exclude a role for viral proteins in
conferring resistance to ISG20. Notably, the S= segment conferred the most substantial
resistance to ISG20, and by P20, a substitution in the N protein (N82T) had been
selected to near uniformity. Because the N protein forms a complex with RNAs from all
segments, it is possible that the N protein influences ISG20 sensitivity. However, in the
ISG20 Inhibits Specific Bunyaviruses Journal of Virology
July 2018 Volume 92 Issue 13 e02140-17 jvi.asm.org 15
 o
n
 N
ovem
ber 21, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
only instance where we assessed protein function (derived from the ISG20-resistant
virus), the mutant NSs protein appeared to be less potent than the parental protein as
an interferon antagonist. Although this is not evidence for RNA-based ISG20 resistance,
it is concordant with this possibility. Put simply, the mechanistic basis for how the P40
virus (or any bunyavirus) resists ISG20 is unknown. Moreover, while progress has been
made (38, 56), the molecular features that define RNAs as sensitive or resistant to
ISG20-mediated inhibition (underlying self-nonself discrimination by ISG20) have yet to
be elucidated fully.
In summary, we have revealed that ISG20 inhibits specific bunyaviruses and have
demonstrated that endogenous ISG20 can potently inhibit BUNV replication. Our study
reinforces the notion that ISG screening is a powerful method for identifying antiviral
effectors. Moreover, the molecular basis of how interferons constrain the replication of
an important group of viral pathogens and how some viruses escape this inhibition
may have impacts on the pathogenesis of bunyaviruses of clinical significance, many of
which cause life-threatening acute febrile illnesses.
MATERIALS AND METHODS
Cells and viruses. MT4 cells were maintained in RPMI 1640 medium (Gibco) supplemented with 9%
fetal bovine serum (FBS) and 100 g/ml gentamicin. BHK-21 cells and BSRT7/5 cells (modified to stably
express T7 RNA polymerase) (66) were grown in Glasgow minimum essential medium (GMEM; Thermo
Fisher Scientific) supplemented with 9% newborn bovine serum (NBS) and FBS, respectively, in addition
to 10% tryptose phosphate broth. BSR-T7/5 cell medium was additionally supplemented with 1 mg/ml
of Geneticin (G418) sulfate (Calbiochem). Vero-E6 (referred to as Vero cells throughout), HeLa, HEK 293T,
and A549-Npro cells (expressing the bovine viral diarrhea virus NPro protein) (67) were maintained in
Dulbecco’s modified Eagle medium (DMEM; Thermo Fisher Scientific) supplemented with 9% FBS. HEK
293T cell medium was also supplemented with 100 g/ml gentamicin.
Fifteen bunyaviruses were used in the study, including BUNV, Cache Valley virus (CVV), Kairi virus
(KRIV), Anopheles A virus (ANAV), Tacaiuma virus (TCMV), Boraceia virus (BORV), Capim virus (CAPV),
Oropouche virus (OROV), Schmallenberg virus (SBV), Batama virus (BMAV), Puumala virus (PUUV), RVFV
(MP12), SFTSV, and heartland virus (HRTV). rBUN-Gc-EGFP (called BUNV-EGFP here) is a recombinant
BUNV in which truncated Gc is tagged with EGFP (46). The single-cycle RVFV system was described
previously (57).
Plasmids. The SCRPSY lentiviral vector (GenBank accession number KT368137) and the human
and macaque ISG libraries have been described previously (43–45). An shRNA-encoding lentiviral vector
targeting ISG20 was generated by PCR, using the human U6 promoter as a template and the following
oligonucleotides: 5=-CTCTCTGAATTCCTGCAGAAGGTCGGGCAGGAAGAGGGCCTA-3= and 5=-TCTCTCGAAT
TCAAAAAGGTGCTGTGCTGTACGACAAGTTCGAAAACTTATCGTACAGCACAGCACCGGTGTTTCGTCCTTTCCA
CAAGATATATAAAG-3=. The PCR product was inserted into CSPW by use of EcoRI (68). The GFP shRNA has
been described previously (68). Plasmids pTM1BUNL, pTM1BUNM, and pTM1BUNN, encoding BUNV
proteins L, M (polyprotein precursor), and N, respectively, and pT7riboBUNLRen(), pT7riboBUNMRen
(), and pT7riboBUNSRen(), used to generate viral genomic-sense minigenomes, have been described
previously (69). Full-length cDNA sequences of the L, M, and S segments were subcloned into plasmid
pTVT7R (0,0) (70) to generate three rescue plasmids: pTVT7 BUNL(), pTVT7 BUNM(), and pTVT7
BUNS().
FACS-based screening. The fluorescence-activated cell sorter (FACS)-based screening assay was
performed in a fashion similar to that for previously described screens (43–45). Briefly, two lentiviral
vector-encoded ISG libraries, consisting of 488 unique ISGs, including 394 human ISGs and 344 macaque
ISGs (43), were used to transduce MT4 cells. Each ISG was expressed from the completely spliced “early”
HIV-1 mRNA, while TagRFP (a surrogate marker for transduction) was expressed from an unspliced late
HIV-1 mRNA (43). This vector format was previously validated, ensuring that RFP-expressing cells were
also ISG positive (using EGFP inserted in place of the ISG) (unpublished observations).
Target MT4 cells were transduced with lentiviral vectors encoding the human and macaque ISGs and
incubated for 48 h (to allow ISG expression) prior to challenge with BUNV-EGFP at an input equivalent
to a multiplicity of infection (MOI) of 5 (Fig. 1C), determined using Vero cells. This dose resulted in an
average of 35% infection. At 48 hpi, cells were collected and fixed with 4% formaldehyde. The
percentage of transduced cells that were infected with BUNV-EGFP was determined by flow cytometry
using a Guava EasyCyte flow cytometer (Millipore).
Lentiviral vector production and transduction assays. Lentiviral stocks were generated in 293T
cells by cotransfection of the SCRPSY lentiviral plasmid, a plasmid expressing HIV-1 NL4-3 gag-pol
(pNLGP), and a plasmid expressing the vesicular stomatitis virus glycoprotein (pVSV-G) at a ratio of 250
ng:25 ng:5 ng in a 96-well plate (for ISG library production) or 5 g:5 g:1 g in a 10-cm dish (for
confirmatory assays). The SCRPSY lentiviral plasmid carries a puromycin resistance gene in a single ORF
together with TagRFP, separated by a foot-and-mouth disease virus (FMDV) 2A “ribosomal skipping”
peptide (PAC2ATagRFP; GenBank accession number ANN89731.1) that facilitated puromycin selection of
transduced cells. Supernatants from 10-cm dishes were collected at 48, 72, and 96 h posttransfection,
clarified by filtration through a 0.22-m filter, and stored at 80°C. For transduction assays, MT4 or Vero
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cells were seeded in either 96-well (40,000 cells/well) or 24-well (120,000 cells/well) plates. Vero cells were
transduced with lentiviral vectors by spinoculation at 1,600 rpm for 1 h. For confirmatory experiments,
new lentiviral stocks were generated for selected ISGs, and the inhibitory effect was measured through
triplicate titrated challenges fixed at 48 hpi (BUNV-EGFP) or 24 hpi (RVFV-EGFP) (57). The ISG-expressing
Vero cells were selected and maintained in medium containing 10 g/ml puromycin.
Virus infection and titration. For assays of infectious yields, cells were seeded in either 12-well or
6-well plates and infected using MOIs of 0.1 to 0.001 (see the figure legends for specific values). The
infected cell culture supernatants were harvested after incubation for 48 or 72 h. Virus titers were
determined by plaque assay. Briefly, cell monolayers were infected with serially diluted virus, incubated
for 1 h at 37°C, and then covered with a 0.6% Avicel (FMC Biopolymer)-minimum essential medium
(MEM) overlay medium supplemented with 2% NBS or FBS. After incubation for 3 to 11 days, depending
on the respective virus, cells were fixed with 4% formaldehyde–phosphate-buffered saline (PBS) and
stained with 0.5% (wt/vol) methyl violet to visualize the plaques. Virus titers were calculated and
presented as numbers of PFU per milliliter. For PUUV only, the foci were visualized using an immunofocus
assay as described previously (4).
Infectious VLP assays. VLP assays were performed as described previously (71), with minor modi-
fications. In brief, BSRT7/5 cells grown in 6-well plates were transfected with plasmids pTM1-BUNVN (0.2
g), pTM1-BUNL (0.3 g), and pTM1-BUNM (0.2 g) and a BUNV-derived minigenome plasmid (0.4 g)
[pT7riboBUNLRen(), pT7riboBUNMRen(), or pT7riboBUNSRen()] by use of TransIT-LT1 transfection
reagent (Mirus). At 24 h posttransfection, supernatants were harvested and clarified at 4,000 rpm for 3
min. Each VLP-containing supernatant was serially diluted and used to infect Vero-ISG cells seeded in
96-well plates. Renilla luciferase activity was measured after a further 24 h of incubation by using a
dual-luciferase assay kit (Promega) according to the manufacturer’s instructions.
Western blotting. Cell lysates were prepared by the addition of SDS sample buffer (20% glycerol,
100 mM Tris-HCl [pH 6.8], 4% SDS, 200 mM dithiothreitol [DTT], 0.2% bromophenol blue). Proteins were
then separated in NuPage 4 to 12% Bis-Tris gradient polyacrylamide gels (Nu-PAGE; Life Technologies)
and wet transferred to a nitrocellulose blotting membrane (GE Healthcare). The membrane was blocked
in Sea Block blocking buffer (Thermo Scientific) for 2 h at room temperature and then probed with a
rabbit anti-human ISG20 polyclonal antibody (PA5-30073; Thermo Fisher Scientific) and a mouse anti-
tubulin monoclonal antibody (T5168; Sigma) at room temperature for 2 h. After washing with PBS-Tween
20, the membrane was subsequently probed with fluorescent secondary antibodies, i.e., IRDye 680RD-
labeled goat anti-rabbit antibody (Thermo Scientific) and IRDye 800CW-labeled goat anti-mouse anti-
body (Li-Cor Biosciences). The blots were scanned using a quantitative Li-Cor Odyssey scanner. The blot
shown in Fig. 3A was created as described previously (4), using antibodies raised against EHD4
(ab153892), SCO2 (ab169042), and LGALS9 (ab153673) from Abcam in addition to antibodies against HK
II (sc-130358), IFTM3 (sc-100768), IRF1 (Sc-135952), NOS2A (Hs sc-7271), and RHOB (sc-8048) from Santa
Cruz. We were unable to establish a Western blot assay for NOS2A or RHOB.
Virus in vitro evolution. Vero-ISG20 cells in T25 flasks were initially infected with the parental BUNV
strain at an MOI of 0.01. After 48 h, the supernatant (passage 1) was used to infect a fresh batch of
Vero-ISG20 cells. Subsequent passages were performed up to passage 40, using an MOI of 0.01. A
parallel passage series was completed using Vero-EMPTY cells (transduced with an “empty” SCRPSY
vector) as the substrate, also for 40 passages to monitor adaptation to transduced Vero cells. The
supernatants were collected and stored at 80°C, and virus titers were determined by plaque assay on
Vero cells.
Virus genome sequencing and 3=-RACE. To determine the genomic sequences of the parental
BUNV and ISG20-resistant BUNV strains, Vero and Vero-ISG20 cells were infected with parental BUNV and
ISG20-resistant BUNV, respectively, at an MOI of 0.1. Cells were lysed in TRIzol (Invitrogen) at 24 hpi, and
total cellular RNA was extracted in accordance with the manufacturer’s instructions. The viral RNA was
subsequently amplified by RT-PCR, using GoScript reverse transcriptase (Promega) and Q5 high-fidelity
DNA polymerase (New England BioLabs), and the sequence was determined by direct sequencing of the
PCR products (Eurofins Genomics).
The sequences of the termini of the viral segments were determined by 3=-RACE. Extracted RNA was
polyadenylated using a poly(A) tailing kit (Ambion) to generate 3=-poly(A)-tailed genomic and antige-
nomic RNAs. cDNA was prepared using oligo(dT). The 3= termini were then PCR amplified using oligo(dT)
(Ambion) and a sequence-specific internal primer. The sequence of the 5= UTR of the genomic RNA was
determined by sequencing the 3= UTR of the antigenomic RNA (as described above). The amplified
fragments were gel purified, and the sequence was determined by Eurofins Genomics.
BUNV S-segment qRT-PCR. Vero-EMPTY, Vero-ISG20, and Vero-ISG20D94G cells were infected with
BUNV at an MOI of 10. At 0, 2, 4, and 6 hpi, cells were lysed in TRIzol and total cellular RNA was extracted
as described above. Following quantification using a NanoDrop 2000 spectrophotometer (Thermo
Scientific), RNAs were reverse transcribed into cDNAs by use of strand-specific tagged RT primers and a
SuperScript III first-strand synthesis system. RNA standards generated from in vitro-transcribed viral
genomic RNA (gRNA), antigenomic RNA (cRNA), and mRNA were used as quantification standards.
Quantitative PCR was performed using Brilliant III Ultra-Fast QPCR master mix from Agilent Technologies
and a Stratagene Mx3005P platform from Agilent Technologies. Each qPCR was performed with a 20-l
reaction volume (6.2 l distilled water [dH2O], 10 l 2 master mix, 0.5 l forward oligonucleotide [10
M], 0.5 l reverse oligonucleotide [10 M], 0.5 l probe [5 M], 0.3 l ROX [1:500 dilution], and 2 l
cDNA template). The qPCR cycling parameters were 95°C for 3 min followed by 40 cycles of 95°C for 10
s and 60°C for 22 s. Each reaction was performed in triplicate. Details of the RT-qPCR primers are listed
in Table 5.
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Virus rescue using reverse genetics. Virus rescues were performed as described previously (72),
with minor modifications. In brief, subconfluent BSRT7/5 cells were transfected with a mixture of
plasmids comprising 1.0 g each of either wild-type or mutant (specified in the relevant figure legends)
pTVT7 BUNL(), pTVT7 BUNM() and pTVT7 BUNS() and 9 l of TransIT-LT1 transfection reagent (Mirus
Bio LLC) in 0.7 ml of Opti-MEM medium (Life Technologies). After 4 h of transfection, 4 ml of growth
medium was added, and incubation was continued for 4 days or until cytopathic effect (CPE) was evident.
Supernatant was harvested and stored at 80°C.
Biological interferon assay. The biological assay for IFN production was performed as described
previously (73). Briefly, “IFN-competent” HeLa cells were infected with different BUNV mutants (MOI  3)
and incubated at 37°C for 24 h. The supernatant was clarified by a brief centrifugation and inactivated
by UV irradiation. The UV-inactivated supernatant was 2-fold serially diluted and used to treat “IFN-
incompetent” A549-Npro cells (expressing the bovine viral diarrhea virus NPro protein). Cells were
infected with encephalomyocarditis virus (EMCV) at an MOI of 0.01, fixed with 8% formaldehyde, and
stained with a methyl violet staining solution (5% [wt/vol]).
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